Neuropace Inc

NPCE remains in a Stage 2 advancing uptrend supported by rising EMAs, but the active Blow-Off Top pattern signals a climax of buying pressure and waning momentum. Short-term price is pulling back into the rising 9/21 EMA support zone on early RSI rollover, making immediate entry unfavorable. We will wait for a cleaner pullback into these dynamic support levels before engaging bullishly.

• ↑Q2 2026 revenue grew 17% YoY to $22.8M, driven by 21.3% RNS system sales growth
• ↑Raised full-year revenue guidance to $99.5–101.5M, signaling management confidence
• ↓Q2 2026 net loss was $6.2M, reflecting persistent cash burn